Assistance Publique Hopitaux De Paris

At Assistance Publique Hopitaux De Paris in Paris, research in digestive system diseases focuses on major liver and gastrointestinal conditions such as unresectable hepatocellular carcinoma, non-alcoholic steatohepatitis, and inflammatory hepatocellular adenomas. These studies are exploring new treatment approaches and ways to improve disease control, imaging outcomes, and overall patient care.

• Hepatocellular carcinoma and other advanced liver tumors
• NASH and liver inflammation
• Inflammatory liver adenomas and tumor shrinkage strategies

The site’s hepato-gastroenterology team is contributing to trials that assess whether new combinations or treatment strategies can better manage complex liver disease and improve outcomes for people with limited current options.

Clinical trials in cardiovascular diseases at this hospital are centered on reducing the risk of serious events in people with atrial fibrillation, atherosclerotic cardiovascular disease, and elevated lipoprotein(a). The research is designed to evaluate whether newer therapies can help prevent heart attack, stroke, and other major complications.

• Atrial fibrillation and prevention of cardioembolic events
• ASCVD with elevated Lp(a)
• Major adverse cardiovascular events prevention

These studies reflect a strong focus on long-term cardiovascular protection, with the goal of improving outcomes for patients at high risk of recurrent heart and vascular events.

A major part of the research portfolio covers neoplasms and hemic and lymphatic diseases, including follicular lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplastic syndrome, and advanced solid tumors such as metastatic colorectal cancer and gastroesophageal adenocarcinoma. These trials are evaluating new treatment options and combinations to improve response rates and survival.

• Follicular lymphoma and marginal zone lymphoma
• Multiple myeloma and myelodysplastic syndrome
• Advanced cancers including colorectal, gastric, and liver tumors

The research includes efforts to test novel therapies, compare treatment combinations, and improve disease control in both blood cancers and difficult-to-treat solid tumors.

Trials in bacterial infections and mycoses and virus diseases address important conditions such as COVID-19, HIV-1 infection, community-acquired pneumonia, mpox, Clostridioides difficile infection, and progressive multifocal leukoencephalopathy. The main aim is to improve treatment effectiveness, prevention, and infection control in both common and complex cases.

• HIV-1 and antiviral treatment options
• COVID-19 and immunocompromised patients
• Antibiotic and infection-management strategies

This area also includes studies on surgical infection prevention and optimized antibiotic use, showing a practical focus on better care for hospitalized patients and those with difficult-to-treat infections.

Research in immune system diseases and musculoskeletal diseases includes giant cell arteritis, Sjögren's syndrome, lupus nephritis, and knee osteoarthritis pain. These trials are investigating new ways to reduce inflammation, ease symptoms, and improve daily functioning.

• Giant cell arteritis and treatment discontinuation strategies
• Sjögren's syndrome and immune control
• Lupus nephritis and inflammatory kidney disease

The work at Assistance Publique Hopitaux De Paris also extends to pain-focused research, where the goal is to find better symptom relief for people living with chronic joint disease.

Additional studies span nutritional and metabolic diseases and other complex clinical areas, including research in obesity-related liver disease, transplant-related prevention, and care for immunocompromised patients. These projects aim to refine supportive care, prevent complications, and improve treatment planning across different specialties.

• Metabolic liver disease and inflammation
• Transplant-related complication prevention
• Supportive care for vulnerable patient groups

The site’s broad trial activity shows an emphasis on practical clinical improvements, from prevention strategies to more personalized approaches for patients with complex and overlapping conditions.